Publication: Thyroid eye disease in Asians and recent advances in management
Issued Date
2020-07-25
Resource Type
ISSN
10006699
Other identifier(s)
2-s2.0-85091601863
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Chinese Journal of Endocrinology and Metabolism. Vol.36, No.7 (2020), 541-562
Suggested Citation
Pimkwan Jaru-Ampornpan, Yu Cheng, Qin Jiao, Raymond S. Douglas Thyroid eye disease in Asians and recent advances in management. Chinese Journal of Endocrinology and Metabolism. Vol.36, No.7 (2020), 541-562. doi:10.3760/cma.j.cn311282-20200123-00039 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/59211
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Thyroid eye disease in Asians and recent advances in management
Abstract
Copyright © 2020 by the Chinese Medical Association. This paper aims to review the current understanding and advances in knowledge of thyroid eye disease(TED)with a focus on Asian population. TED can significantly impact quality of life, and has devastating consequences, including facial disfigurement and vision loss. Recent findings revealed a novel targeted therapy against TED, including teprotumumab, a human monoclonal antibody that inhibits the insulin-like growth factor-1 receptor. Teprotumumab was found to reverse the disease process in patients with active, moderate-to-severe TED. A randomized clinical trial of this drug compared to placebo showed significant improvement in clinical activity score, proptosis, subjective diplopia, and quality of life at 4 months follow-up in the treatment group. In this paper, we review the current epidemiology, pathophysiology, and advances in management of TED.